New research in Nature Communications: Dr. Park's lab delineates novel molecular pathway in Parkinson’s pathogenesis.
A team of researchers from the University of Ottawa Faculty of Medicine, led by Dr. Park, has delineated the mechanism by which a gene mutation leads to a form of Parkinson’s disease—namely, the loss of the PINK1 gene. Their findings were published today in Nature Communications, of the highly prestigious Nature family of journals.
Dr. Harold Atkins awarded the Till & McCulloch Award
Dr. Harold Atkins accepted the Till & McCulloch Award, Canada’s top prize for stem cell research. He was interviewed by the Ottawa Citizen about his ground-breaking clinical trial of stem cell transplantation for multiple sclerosis, co-led with Dr. Mark Freedman.
Dr. Roger Zemek explores differences in concussion symptoms
Dr. Roger Zemek was the lead researcher on a comprehensive study involving more than 3,000 children between ages 5 and 18. More than 8,000 children were screened for this study, which was published in the Journal of the American Medical Association (JAMA) in 2016 and gathered data from five centres, including Ottawa.
Dr. Schlossmacher honoured with the 2017 Grimes Research Career Achievement Award
Dr. Michael Schlossmacher grew up in Austria, trained at Harvard and now leads The Ottawa Hospital’s neuroscience research program. His research helped establish a key concept in Alzheimer’s disease and led to a clinical trial of an experimental therapy for Parkinson’s. He is now investigating the link between Parkinson’s and immune system. He will receive the Grimes Research Career Achievement Award from the hospital on October 28, 2017.
$10 million boost for research on neuromuscular diseases and virus-based therapies
Ottawa researchers have been awarded nearly $10 million from the Canada Foundation for Innovation for new equipment and facilities to support cutting-edge research on neuromuscular diseases and virus-based therapies. “This funding will help us build on recent breakthroughs in our understanding of neuromuscular diseases, design much-needed new therapies and evaluate them in patients,” said Dr. Rashmi Kothary, who leads the $4 million neuromuscular project together with Dr. Bernard Jasmin.
Award-winning tool helps predict course of recovery from spinal cord injury
“Will I ever walk again?” is one of the first questions a person asks after a spinal cord injury. Because each person’s recovery is different, it’s often hard for physicians to predict what an individual will be able to do in the future. Dr. Philippe Phan’s team, including Drs. Eugene Wai, Eve Tsai and Darren Roffey and contributors from across the country, has made answering this question easier by simplifying an existing prediction tool.